Liver Disease Treatment Market

Liver Disease Treatment Market Size Survey Report – In a Glance

As per the survey report on the global Liver Disease Treatment Market, the market is projected to foresee a CAGR of 6.2% between 2024-2033, and further generate a market size of USD 37.3 billion revenue by the end of 2033. In the year 2024, the market size was valued at USD 19.2 billion revenue.

• The global Liver Disease Treatment Market is projected to grow on account of fluctuating dietary habits.
• In Japan, the increasing geriatric population, can be attributed to the growth in the Liver Disease Treatment Market.
• KDMI analyst’s growth analysis foresees stringent regulation to challenge market growth.
• North America, having the highest market share in the Liver Disease Treatment Market, is projected to dominate the global market.

Liver Disease Treatment Market Analysis

Liver disease treatment depends on the severity of the disease. The doctor might advise lifestyle shifts such as discontinuing drinking alcohol altogether, preventing taking over-the-counter medicine medicines or pain killers, minimizing weight and decreasing the volume of fatty foods in everyday diet. Poor or fluctuating dietary habits are one of the significant growth drivers of the liver disease treatment market. An unhealthy diet shifts the gut microbiota, leading to the formation of pathogenic factors which affect the liver. With the consumption of foods high in sugar and fat, a gut bacteria namely Blautia Producta and a kind of lipid are produced in the liver, which results in liver fibrosis and inflammation. As of 2019, around 11 million deaths every year are associated with diet-prone diseases. The growing dietary fluctuation bodes well for the development of liver diseases, eventually propelling the demand for liver disease treatment services. Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, and Eli Lilly are significant companies in the global Liver Disease Treatment Market.

Analyst’s Observation on Japan Liver Disease Treatment Market Survey

Ageing has been denoted to improve vulnerability to severe liver injury but even upsurge exposure towards the fibrotic response. The ageing population has been linked with the sternness and poor prognosis of numerous liver diseases involving alcoholic liver disease, fatty liver disease, liver transplantation and hepatitis C. The increase in the ageing population of Japan pushes the liver disease treatment market in the region. The proportion of elderly Japanese people increased by 20,000 from September 2023 to 36.25 million, registering for record high of about 29.3% of the entire population. The high prevalence of liver disease in Japan is another factor propelling the liver disease market in the region. Hepatitis C virus is the chief cause of hepatocellular carcinoma and liver cirrhosis in Japan. Otsuka Pharmaceuticals Co., Ltd, Healios K.K, and Okayama University Hospital are significant companies in the Japanese Liver Disease Treatment market.

Liver Disease Treatment Market Growth Driver & Market Restraint

Growth Driver

Increasing emphasis on non-alcoholic fatty liver disease:

Due to a continuous upsurge in the cases of diabetes and obesity, NAFLD cases have witnessed a rise, and have become the chief focus centre in liver disease treatment. NAFLD is the 3rd most common reason for cancer-related deaths globally, and its increasing pressure might enhance the incidence of mortality and hepatocellular carcinoma. Many therapies and research have been supported by the global government to fight nonalcoholic fatty liver disease. The launch of Indo French Node, InFLiMeN, targets to address chief problems associated with a common metabolic liver illness. Patient engagement is linked with long-term accomplishment in handling chronic situations such as NAFLD. It encourages sustained behaviour shifts, resulting in enhanced health outcomes. In order to improve community-level awareness, raising podiums such as meetings of Gram Sabha is used along with traditional media such as Kala Jathas. Government intervention has boosted the liver disease (NAFLD) market globally.

Growing focus on pharmaceutical expansion:

Pharmaceutical companies’ responses to the growing rate of liver diseases are through increased research & development to generate novel treatments that concentrate on the root reason of liver illnesses such as new medication and therapy. Globally, China is the world’s 2nd largest region by pharmaceutical investment as of 2023 and it is expected to increase by 8% in aggregate over the 5 years. With the expansion of pharmaceutical expansion, remarkable progress has been made in the treatment of viral hepatitis, especially hepatitis C virus infection. The launch of direct-acting antivirals has transformed HCV treatment, with cure rates surpassing 95% for the most genetic constitution. Such novel liver disease therapies have lesser treatment duration, are well tolerated and are efficient even in patients with progressive liver disease. Numerous novel liver disease therapies are in late-phase clinical trials. One of the promising drug candidates aims to distinguish aspects of NASH pathogenesis, including fibrosis and inflammation.

Market Restraint

Stringent regulation:

Stringent regulations, while critical for patient’s security, represent a considerable challenge in the liver disease treatment market and it involves postponement in drug approvals, upsurged development costs and probable restriction in accessing ground-breaking therapies.

Drug complication:

Drug induced liver injury stays a challenge in clinical practice and is a diagnosis of exclusion. Clinicals progressively face the trial of security prescribing medicines to patients suffering cirrhosis because of the chronic liver disease.

Liver Disease Treatment Market Segmentation

Our experts at KD Market Insights have segmented the global Liver Disease Treatment Market research report as:

Liver Disease Treatment Market Regional Synopsis

The North America dominated the liver disease treatment market due to intense government funding. As on 14th March 2024 the United States Food and Drug Administration approved Rezdiffa for the adult treatment with noncirrhotic non alcoholic steatohepatitis with modest to progressive liver fibrosis, to be applied along with exercise and diet. High prevalence of liver disease in United States is another reason for the growth of liver disease treatment market in the country. Around 4.5 million United States adults were found to have liver disease. Further, around 80 to 100 million adults in the United States have fatty liver diseases and they unaware of this. Prevalence of chronic diseases such as diabetes and obesity in United States, stimulates the growth of liver disease treatment market in the country. As of 2023, the prevalence of diabetes upsurged to 11.5% of adult affecting about 37.3 million people.

Asia Pacific is expected to have the fastest growth in liver disease treatment due to increasing demand for liver transplants. Living donor liver transplants have advanced rapidly in regions such as India, having 2 major centres performing around 200 transplants every year. It has grown tremendously in the past decade having 135 centers performing presently 1500 to 2000 transplants annually. The high prevalence of liver diseases such as hepatitis and by measuring country-specific HBsAG prevalence as of 2021 by provincial population size, the nationwide HBsAG seroprevalence stayed very uniform, about 3.0%, equal to 43.3 million HBV carriers as of China in 2021. The progressing state of liver transplantation in South Korea is resulting in the success of the liver disease treatment market. The 3-year and 5-year rates of survival in the region are excellent, reaching 83.7% and 80.9% for LDLT and 72.3% and 68.9% for DDLT.

Growing awareness about liver diseases is one of the fundamental reasons of the growth of liver disease treatment market in Europe. Government and pharmaceuticals have been investing actively for supporting new innovations and researches. In the UK, the Medicine and Healthcare products Regulatory Agency (MHRA) regulates medicines, security and cost efficiency of liver disease treatment, eventually pushing its market. In Middle East and North Africa, the liver disease treatment market is flourishing due to bad lifestyle choices.

Liver Disease Treatment Market Competitive Landscape

Some of the key players who have the top global Liver Disease Treatment Market share:

• Abbott Laboratories
• AbbVie Inc
• Astellas Pharma Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Emergent BioSolutions Inc.
• F. Hoffmann-La Roche AG
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Merck & Co. Inc.

1. Executive Summary
   1. Market Overview
   2. Key Findings
   3. Market Trends
   4. Market Outlook
2. Introduction
   1. Scope of the Report
   2. Research Methodology
   3. Definitions and Assumptions
   4. Acronyms and Abbreviations
3. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
   4. Challenges
4. Global Air Freshener Market
   1. Market Overview
   2. Market Size and Forecast
   3. Market Segmentation
      1. By Treatment Type
      2. By Disease Type
      3. By End use
      4. By Region
5. Market Segmentation by Treatment Type
   1. Antiviral drugs
   2. Targeted therapy,
   3. Immunosuppressant drugs
   4. Chemotherapy drugs
   5.  Immunoglobulin
   6. Vaccines
   7. Other
6. Market Segmentation by Disease Type
   1. Hepatitis
   2. Autoimmune Diseases
   3. Non-alcoholic Fatty Liver Disease (NAFLD)
   4. Cancer
   5. Genetic Disorders
   6. Others
7. Market Segmentation by End Use
   1. Hospitals
   2. Ambulatory Surgical Centers
   3. Others
8. Regional Analysis
   1. North America
      1. United States
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      2. Canada
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      3. Mexico
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
   2. Europe
      1. United Kingdom
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      2. Germany
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      3. France
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      4. Italy
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      5. Spain
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      6. Rest of Europe
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
   3. Asia Pacific
      1. China
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      2. Japan
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      3. India
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      4. Australia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      5. South Korea
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      6. Rest of Asia Pacific
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
   4. Latin America
      1. Brazil
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      2. Argentina
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      3. Colombia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      4. Rest of Latin America
         1. Market Size and Forecast
         2. Key Trends and Developments
         3.               Market Analysis by Treatment Type, Disease Type and End Use         
   5. Middle East & Africa
      1. South Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      2. Saudi Arabia
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use          
      3. UAE
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
      4. Rest of Middle East & Africa
         1. Market Size and Forecast
         2. Key Trends and Developments
         3. Market Analysis by Treatment Type, Disease Type and End Use         
9. Competitive Landscape
   1. Market Share Analysis
   2. Company Profiles
      1. Air Liquide
      2. Abbott Laboratories
      3. AbbVie Inc
      4. Astellas Pharma Inc.
      5. Bristol-Myers Squibb Company
      6. Eli Lilly and Company
      7. Emergent BioSolutions Inc.
      8. F. Hoffmann-La Roche AG
      9. Gilead Sciences Inc.
      10. GlaxoSmithKline plc
      11. Merck & Co. Inc.
      12. Others
10. Strategic Recommendations
11. Appendix
    1. List of Tables
    2. List of Figures
12. References